- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00504101
Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma
Phase I Clinical Trial of Dose Escalated Bortezomib + ATO (Arsenic Trioxide) + Melphalan as a Conditioning Regimen for Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as arsenic trioxide and melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving high-dose combination chemotherapy together with bortezomib may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib when given together with arsenic trioxide and melphalan in treating patients undergoing an autologous stem cell transplant for multiple myeloma.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
OBJECTIVES:
Primary
- Evaluate toxicity of a conditioning treatment regimen comprising bortezomib, arsenic trioxide, and melphalan.
Secondary
- Evaluate response and overall survival.
- Determine what correlative laboratory and clinical parameters, if any, are associated with efficacy (e.g., serum arsenic trioxide intracellular glutathione depletion, gene profiling of myeloma cells).
OUTLINE: This is a dose-escalation study of bortezomib.
- Conditioning regimen: Bortezomib will be given on days -6, -4, and -2, arsenic trioxide will be given on days -6, -5, -4, -3, and -2 (total of 5 doses), and melphalan will be given on day -2.
- Stem cell infusion: On day 0 a minimum of autologous 2 x 10^6 CD34 cells/kg will be infused by central catheter.
After completion of study therapy, patients are followed periodically for at least 5 years.
Studietyp
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
Florida
-
Miami, Florida, Förenta staterna, 33136
- University of Miami Sylvester Comprehensive Cancer Center - Miami
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
DISEASE CHARACTERISTICS:
Inclusion criteria:
Confirmed diagnosis of multiple myeloma (M-protein by serum protein electrophoresis or urine protein electrophoresis) and either bone marrow biopsy and aspirate demonstrating a plasma cell count > 10% or biopsy of a bone or soft tissue mass demonstrating a plasmacytoma
- Demonstration of an indication for therapy based on symptoms (e.g., boney pain), hypercalcemia, anemia, renal insufficiency, symptomatic plasmacytomas, multiple boney lytic lesions, etc
- Stable disease or has achieved a partial remission or complete remission to pre-transplant cyto-reductive therapy
- Primary refractory disease (no response to therapy but stable) is permitted
- Candidate for high-dose chemotherapy with autologous stem cell transplantation based on stabilization of disease with preparative chemotherapy (regardless of the specific agents)
- A minimum of 2 x 10^6 CD34+ cells/kg must be collected prior to proceeding to transplant
Exclusion criteria:
- Evidence of active plasma cell leukemia
- Relapsed refractory disease (patients who have achieved at least a partial response [PR] to previous therapy and are now refractory [have not achieved a PR to subsequent therapy])
- Progressive disease on their last therapy
PATIENT CHARACTERISTICS:
Inclusion criteria:
- Karnofsky performance status 60-100%
- Creatinine < 3.0 mg/dL
- AST and ALT <2.5 times upper limit of normal
- Total bilirubin < 3 mg/dL
- WBC ≥ 2,000/mm³
- Platelet count ≥ 50,000/mm³
- If abnormal hematologic function is attributable to bone marrow infiltration by multiple myeloma, the principal investigator will decide on a case-by-case basis if the patient's bone marrow reserve is appropriate for this study
- Females of childbearing potential must have a negative serum pregnancy test prior to enrollment on the study and must use an effective barrier method while on the study
- Ejection fraction > 40% and no history of uncontrolled ischemic heart disease or congestive heart failure
- No evidence of cardiac amyloidosis by echocardiogram
- DLCO and FEV_1 ≥ 50%
Exclusion criteria:
- Active peripheral neuropathy ≥ grade 2
- Recurrent supraventricular arrhythmia or any type of sustained ventricular arrhythmia or conduction block (e.g., A-V block grade II or III, left bundle branch block)
- Known HIV infection
- Pregnant or lactating women
- Underlying medical condition that could be aggravated by the treatment or life-threatening disease unrelated to myeloma as evaluated by the enrolling physician
- History of second malignancy within the past 3 years and not in complete remission from that malignancy, excluding adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or local prostate cancer
- History of preexisting neurological disorders (grade 2 or higher by the NCI Common Toxicity Criteria, in particular seizure disorders)
PRIOR CONCURRENT THERAPY:
Inclusion criteria:
- Previous radiation therapy for palliation of cord compression or pathologic fractures is permitted provided last dose is given 14 days prior to initiation of chemotherapy
Subjects with radiographic evidence of lytic bone disease receiving concomitant bisphosphonate therapy may be enrolled
- Bisphosphonates should be held at least 1 week prior to the transplant but continuing bisphosphonates after day +60 is at the discretion of the treating physician
Exclusion criteria:
- Previous autologous or allogeneic transplantation
- Other investigational or experimental drug or therapy while on the study
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Evaluate toxicity of the conditioning treatment regimen.
Tidsram: 3 ¼ years
|
3 ¼ years
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Evaluate response and overall survival (OS).
Tidsram: 3 ¼ years
|
3 ¼ years
|
Determine what correlative laboratory and clinical parameters, if any, are associated with efficacy
Tidsram: 3 ¼ years
|
3 ¼ years
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studiestol: Mark S. Goodman, MD, University Of Miami Sylvester Comprehensive Cancer Center
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Hjärt-kärlsjukdomar
- Kärlsjukdomar
- Immunsystemets sjukdomar
- Neoplasmer efter histologisk typ
- Neoplasmer
- Lymfoproliferativa störningar
- Immunproliferativa störningar
- Hematologiska sjukdomar
- Hemorragiska störningar
- Hemostatiska störningar
- Paraproteinemier
- Blodproteinstörningar
- Multipelt myelom
- Neoplasmer, Plasmacell
- Plasmacytom
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Antineoplastiska medel
- Immunsuppressiva medel
- Immunologiska faktorer
- Antineoplastiska medel, Alkylering
- Alkyleringsmedel
- Myeloablativa agonister
- Melphalan
- Bortezomib
- Arseniktrioxid
Andra studie-ID-nummer
- 20070104 (BiPar)
- SCCC-2006071 (Annan identifierare: University of Miami Sylvester Comprehensive Cancer Center)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Multipelt myelom och plasmacellsneoplasma
-
The Cleveland ClinicIndragenSteg I multipelt myelom | Steg II multipelt myelom | Steg III multipelt myelom | Refractory Plasma Cell NeoplasmFörenta staterna
-
Mayo ClinicNational Cancer Institute (NCI)RekryteringÅterkommande Hodgkin-lymfom | Refraktärt Hodgkin-lymfom | Refraktärt plasmacellsmyelom | Återkommande histiocytisk och dendritisk cellneoplasma | Återkommande non-Hodgkin lymfom | Refractory Histiocytic and Dendritic Cell Neoplasm | Refraktärt non-Hodgkin lymfom | Återkommande plasmacellsmyelomFörenta staterna
-
OncotherapeuticsIndragenSteg II multipelt myelom | Steg III multipelt myelom | Refractory Plasma Cell NeoplasmFörenta staterna
-
National Cancer Institute (NCI)AvslutadSteg II multipelt myelom | Steg III multipelt myelom | Refractory Plasma Cell NeoplasmFörenta staterna
-
Columbia UniversityNational Cancer Institute (NCI)AvslutadLymfom | Myelodysplastiska syndrom | Leukemi | Multipelt myelom och plasmacellsneoplasma | Myelodysplastiska/myeloproliferativa neoplasmer | Barndom Langerhans cell Histiocytos | Vuxen Langerhans cell HistiocytosFörenta staterna
-
Herbert Irving Comprehensive Cancer CenterNational Cancer Institute (NCI)OkändLymfom | Myelodysplastiska syndrom | Leukemi | Multipelt myelom och plasmacellsneoplasma | Myelodysplastiska/myeloproliferativa neoplasmer | Barndom Langerhans cell HistiocytosFörenta staterna
-
National Heart, Lung, and Blood Institute (NHLBI)AvslutadMultipelt myelom | Kronisk lymfatisk leukemi | Myelodysplastiskt syndrom | Graft vs Host Disease | Hematologisk neoplasmFörenta staterna
-
University of California, San FranciscoAvslutadRefraktärt plasmacellsmyelom | Återkommande diffust stort B-cellslymfom | Refraktärt diffust stort B-cellslymfom | Återkommande plasmacellsmyelom | Återkommande malign neoplasm | Refraktär malign neoplasm | Återkommande höggradigt B-cellslymfom | Refraktärt höggradigt B-cellslymfom | Återkommande aggressivt... och andra villkorFörenta staterna
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)AvslutadAkut myeloid leukemi | Hodgkins lymfom | Waldenström Makroglobulinemi | Akut lymfoblastisk leukemi | Kronisk lymfatisk leukemi | Non-Hodgkin lymfom | Plasmacellmyelom | Myelodysplastisk/myeloproliferativ neoplasma | Graft kontra värdsjukdom | Kronisk myelogen leukemi, BCR-ABL1 positivFörenta staterna, Italien
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)RekryteringDiffust stort B-cellslymfom | Akut myeloid leukemi | Återkommande Hodgkin-lymfom | Akut lymfoblastisk leukemi | Mantelcellslymfom | Kronisk lymfatisk leukemi | Myelodysplastiskt syndrom | Återkommande litet lymfocytiskt lymfom | Blastisk Plasmacytoid Dendritic Cell Neoplasm | Prolymfocytisk leukemi | Återkommande... och andra villkorFörenta staterna